ImmuCell Corporation (ICCC) — This stock currently has no analyst coverage. No price targets, ratings, or earnings estimates are available. This is common for preferred shares, warrants, OTC-traded securities, and smaller companies that are not followed by Wall Street analysts.
分析师预估 每股收益(EPS)为 $-0.11 和 营收为 $0.02B (下一财年).
每股收益(EPS)历史表现: 2024: 实际 $-0.26 vs 预期 $-0.11 (不及预期 -136.4%). 2025: 实际 $-0.12 vs 预期 $-0.24 (超预期 +50%). 分析师准确度: 21%.
EPS 预测 — ICCC
21%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual –$0.26
vs Est –$0.11
▼ 57.7% off
2025
Actual –$0.12
vs Est –$0.24
▲ 100.0% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
营收预测 — ICCC
64%
Analyst Accuracy
Fair
2 years compared
Actual vs Estimate
2024
Actual $0.026B
vs Est $0.019B
▲ 27.5% off
2025
Actual $0.028B
vs Est $0.015B
▲ 45.2% off
Revenue Trend
Revenue has been relatively flat. Analysts forecast revenue contraction ahead.
